Thierry Pascale, Lasserre Andrea, Rossignol Louise, Kernéis Solen, Blaizeau Fanette, Stheneur Chantal, Blanchon Thierry, Levy-Bruhl Daniel, Hanslik Thomas
a INSERM ; Paris , France.
b Sorbonne Universités; UPMC Univ Paris 06 ; Paris , France.
Hum Vaccin Immunother. 2016;12(2):528-33. doi: 10.1080/21645515.2015.1078042.
In France, vaccination against human papilloma virus (HPV) was recommended in 2007 for all 14-year-old girls as well as "catch-up" vaccination for girls between 15-23 y of age either before or within one year of becoming sexually active. We evaluated the vaccine coverage according to the eligibility for vaccination in a sample of young girls aged 14 to 23 years, who were seen in general practices. A survey was proposed to 706 general practitioners (GPs) and carried out from July to September 2010. GPs, also called "family doctor," are physicians whose practice is not restricted to a specific field of medicine but instead covers a variety of medical problems in patients of all ages. Each participating GP included, retrospectively, the last female patient aged 14-17 y and the last female patient aged 18-23 y whom he had seen. A questionnaire collected information regarding the GP and the patients' characteristics. The vaccine coverage was determined according to the eligibility for vaccination, i.e. the coverage among younger women (14-17) and among those sexually active in the second age range (18-23). Sexual activity status was assessed by GP, according to information stated in the medical record. The 363 participating physicians (response rate 51.4%) included 712 patients (357 in the 14- to 17-year-old group and 355 in the 15- to 23-year-old group) in their responses. The rate of the vaccination coverage in the 14- to 17-year-old group was 55%. Among the girls in the 18- to 23-year-old group, 126 were eligible, and their vaccination coverage rate was 82%. The evaluation of the eligibility by the GPs was incorrect in 36% of the cases. Of the 712 patients, 6% of the girls had been vaccinated without a need for the vaccination, and 26% of the girls had not been vaccinated, although they needed to be vaccinated. Regarding the vaccine uptake, vaccination at the age of 14 was not as effective as vaccinating the older population for which vaccination was indicated as a catch-up program, based on sexual history. However, in more than one-third of the older population, difficulties remained regarding the determination of eligibility, according to the sexual history of the patient.
2007年,法国建议所有14岁女孩接种人乳头瘤病毒(HPV)疫苗,并建议15至23岁的女孩在开始性行为前或开始性行为后一年内进行“补种”疫苗接种。我们根据一般诊疗中14至23岁年轻女孩的疫苗接种资格评估了疫苗接种覆盖率。向706名全科医生(GPs)提出了一项调查,并于2010年7月至9月开展。全科医生,也被称为“家庭医生”,其业务不限于特定医学领域,而是涵盖各年龄段患者的各种医疗问题。每位参与的全科医生回顾性纳入了他接诊的最后一名14至17岁女性患者和最后一名18至23岁女性患者。一份问卷收集了有关全科医生和患者特征的信息。疫苗接种覆盖率根据疫苗接种资格确定,即较年轻女性(14至17岁)以及第二年龄组(18至23岁)中有性行为女性的接种覆盖率。性行为状况由全科医生根据病历中所述信息进行评估。363名参与的医生(回复率51.4%)在回复中纳入了712名患者(14至17岁组357名,15至23岁组355名)。14至17岁组的疫苗接种率为55%。在18至23岁组的女孩中,126名符合接种条件,她们的疫苗接种率为82%。全科医生对接种资格的评估在36%的病例中是错误的。在712名患者中,6%的女孩在不需要接种疫苗的情况下接种了疫苗,26%的女孩尽管需要接种疫苗但未接种。关于疫苗接种情况,根据性病史,14岁时接种疫苗不如为年龄较大人群接种疫苗有效,年龄较大人群的接种是作为补种计划进行的。然而,在超过三分之一的年龄较大人群中,根据患者的性病史确定接种资格仍存在困难。